Evaluation of the Safety of Everolimus-Eluting Bioresorbable Vascular Scaffold (BVS) Implantation in Patients with Chronic Total Coronary Occlusions

Acute Procedural and Short-Term Clinical Results

Omer Goktekin, Aylin Hatice Yamac, Azeem Latib, Ahmet Tastan, Vasileios F. Panoulas, Katsumasa Sato, Ercan Erdogan, Huseyin Uyarel, Ibrahim Shah, Antonio Colombo

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

AIMS: The bioresorbable vascular scaffold (BVS) (Abbott Vascular) provides temporary scaffolding while eluting everolimus. There are limited data on its use in daily practice, especially in patients with stable angina pectoris referred for elective percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs). The current study aims to investigate the safety and efficacy of BVS implantation in a selected patient cohort with CTO. METHODS: A total of 70 consecutive patients, who underwent successful recanalization of CTO with BVS between September 13, 2012 and September 20, 2014 in three cardiac centers (Department of Cardiology, Bezmialem Vakif University, Istanbul, Turkey; Department of Interventional Cardiology, San Raffaele Hospital, Milan, Italy; and EMO-GVM Centro Cuore Columbus, Milan, Italy) were included in this CTO registry. Endpoints analyzed included: (1) the composite of all-cause death and non-fatal myocardial infarction (MI); and (2) the composite safety endpoint of major adverse cardiovascular events (MACEs), including death, MI and symptom-driven target lesion revascularization (TLR). RESULTS: Clinical data were obtained for 70 patients (mean age, 56.9 ± 9.4 years; 90.0% male) with a total number of 76 CTOs. At a median follow-up of 11.0 months (interquartile range, 7-18 months), both MACE and TLR rates were 4.3%. Two patients suffered from ischemia-driven TLR (1 patient at 6 months and 1 patient at 9 months after implantation). No death, MI, or stent thrombosis was observed during the follow-up period. CONCLUSION: Treatment of CTOs with BVS seems to be safe and effective, with a high technical success rate and acceptable MACE at short-term follow-up.

Original languageEnglish
Pages (from-to)461-466
Number of pages6
JournalJournal of Invasive Cardiology
Volume27
Issue number10
Publication statusPublished - Oct 1 2015

Fingerprint

Coronary Occlusion
Blood Vessels
Safety
Myocardial Infarction
Cardiology
Italy
Stable Angina
Percutaneous Coronary Intervention
Turkey
Everolimus
Stents
Registries
Cause of Death
Thrombosis
Ischemia

Keywords

  • bioresorbable vascular scaffold
  • chronic total occlusion
  • efficacy and safety

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Evaluation of the Safety of Everolimus-Eluting Bioresorbable Vascular Scaffold (BVS) Implantation in Patients with Chronic Total Coronary Occlusions : Acute Procedural and Short-Term Clinical Results. / Goktekin, Omer; Yamac, Aylin Hatice; Latib, Azeem; Tastan, Ahmet; Panoulas, Vasileios F.; Sato, Katsumasa; Erdogan, Ercan; Uyarel, Huseyin; Shah, Ibrahim; Colombo, Antonio.

In: Journal of Invasive Cardiology, Vol. 27, No. 10, 01.10.2015, p. 461-466.

Research output: Contribution to journalArticle

Goktekin, O, Yamac, AH, Latib, A, Tastan, A, Panoulas, VF, Sato, K, Erdogan, E, Uyarel, H, Shah, I & Colombo, A 2015, 'Evaluation of the Safety of Everolimus-Eluting Bioresorbable Vascular Scaffold (BVS) Implantation in Patients with Chronic Total Coronary Occlusions: Acute Procedural and Short-Term Clinical Results', Journal of Invasive Cardiology, vol. 27, no. 10, pp. 461-466.
Goktekin, Omer ; Yamac, Aylin Hatice ; Latib, Azeem ; Tastan, Ahmet ; Panoulas, Vasileios F. ; Sato, Katsumasa ; Erdogan, Ercan ; Uyarel, Huseyin ; Shah, Ibrahim ; Colombo, Antonio. / Evaluation of the Safety of Everolimus-Eluting Bioresorbable Vascular Scaffold (BVS) Implantation in Patients with Chronic Total Coronary Occlusions : Acute Procedural and Short-Term Clinical Results. In: Journal of Invasive Cardiology. 2015 ; Vol. 27, No. 10. pp. 461-466.
@article{ac9773fe06d7449189b3fe1f547c41bc,
title = "Evaluation of the Safety of Everolimus-Eluting Bioresorbable Vascular Scaffold (BVS) Implantation in Patients with Chronic Total Coronary Occlusions: Acute Procedural and Short-Term Clinical Results",
abstract = "AIMS: The bioresorbable vascular scaffold (BVS) (Abbott Vascular) provides temporary scaffolding while eluting everolimus. There are limited data on its use in daily practice, especially in patients with stable angina pectoris referred for elective percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs). The current study aims to investigate the safety and efficacy of BVS implantation in a selected patient cohort with CTO. METHODS: A total of 70 consecutive patients, who underwent successful recanalization of CTO with BVS between September 13, 2012 and September 20, 2014 in three cardiac centers (Department of Cardiology, Bezmialem Vakif University, Istanbul, Turkey; Department of Interventional Cardiology, San Raffaele Hospital, Milan, Italy; and EMO-GVM Centro Cuore Columbus, Milan, Italy) were included in this CTO registry. Endpoints analyzed included: (1) the composite of all-cause death and non-fatal myocardial infarction (MI); and (2) the composite safety endpoint of major adverse cardiovascular events (MACEs), including death, MI and symptom-driven target lesion revascularization (TLR). RESULTS: Clinical data were obtained for 70 patients (mean age, 56.9 ± 9.4 years; 90.0{\%} male) with a total number of 76 CTOs. At a median follow-up of 11.0 months (interquartile range, 7-18 months), both MACE and TLR rates were 4.3{\%}. Two patients suffered from ischemia-driven TLR (1 patient at 6 months and 1 patient at 9 months after implantation). No death, MI, or stent thrombosis was observed during the follow-up period. CONCLUSION: Treatment of CTOs with BVS seems to be safe and effective, with a high technical success rate and acceptable MACE at short-term follow-up.",
keywords = "bioresorbable vascular scaffold, chronic total occlusion, efficacy and safety",
author = "Omer Goktekin and Yamac, {Aylin Hatice} and Azeem Latib and Ahmet Tastan and Panoulas, {Vasileios F.} and Katsumasa Sato and Ercan Erdogan and Huseyin Uyarel and Ibrahim Shah and Antonio Colombo",
year = "2015",
month = "10",
day = "1",
language = "English",
volume = "27",
pages = "461--466",
journal = "Journal of Invasive Cardiology",
issn = "1042-3931",
publisher = "HMP Communications",
number = "10",

}

TY - JOUR

T1 - Evaluation of the Safety of Everolimus-Eluting Bioresorbable Vascular Scaffold (BVS) Implantation in Patients with Chronic Total Coronary Occlusions

T2 - Acute Procedural and Short-Term Clinical Results

AU - Goktekin, Omer

AU - Yamac, Aylin Hatice

AU - Latib, Azeem

AU - Tastan, Ahmet

AU - Panoulas, Vasileios F.

AU - Sato, Katsumasa

AU - Erdogan, Ercan

AU - Uyarel, Huseyin

AU - Shah, Ibrahim

AU - Colombo, Antonio

PY - 2015/10/1

Y1 - 2015/10/1

N2 - AIMS: The bioresorbable vascular scaffold (BVS) (Abbott Vascular) provides temporary scaffolding while eluting everolimus. There are limited data on its use in daily practice, especially in patients with stable angina pectoris referred for elective percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs). The current study aims to investigate the safety and efficacy of BVS implantation in a selected patient cohort with CTO. METHODS: A total of 70 consecutive patients, who underwent successful recanalization of CTO with BVS between September 13, 2012 and September 20, 2014 in three cardiac centers (Department of Cardiology, Bezmialem Vakif University, Istanbul, Turkey; Department of Interventional Cardiology, San Raffaele Hospital, Milan, Italy; and EMO-GVM Centro Cuore Columbus, Milan, Italy) were included in this CTO registry. Endpoints analyzed included: (1) the composite of all-cause death and non-fatal myocardial infarction (MI); and (2) the composite safety endpoint of major adverse cardiovascular events (MACEs), including death, MI and symptom-driven target lesion revascularization (TLR). RESULTS: Clinical data were obtained for 70 patients (mean age, 56.9 ± 9.4 years; 90.0% male) with a total number of 76 CTOs. At a median follow-up of 11.0 months (interquartile range, 7-18 months), both MACE and TLR rates were 4.3%. Two patients suffered from ischemia-driven TLR (1 patient at 6 months and 1 patient at 9 months after implantation). No death, MI, or stent thrombosis was observed during the follow-up period. CONCLUSION: Treatment of CTOs with BVS seems to be safe and effective, with a high technical success rate and acceptable MACE at short-term follow-up.

AB - AIMS: The bioresorbable vascular scaffold (BVS) (Abbott Vascular) provides temporary scaffolding while eluting everolimus. There are limited data on its use in daily practice, especially in patients with stable angina pectoris referred for elective percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs). The current study aims to investigate the safety and efficacy of BVS implantation in a selected patient cohort with CTO. METHODS: A total of 70 consecutive patients, who underwent successful recanalization of CTO with BVS between September 13, 2012 and September 20, 2014 in three cardiac centers (Department of Cardiology, Bezmialem Vakif University, Istanbul, Turkey; Department of Interventional Cardiology, San Raffaele Hospital, Milan, Italy; and EMO-GVM Centro Cuore Columbus, Milan, Italy) were included in this CTO registry. Endpoints analyzed included: (1) the composite of all-cause death and non-fatal myocardial infarction (MI); and (2) the composite safety endpoint of major adverse cardiovascular events (MACEs), including death, MI and symptom-driven target lesion revascularization (TLR). RESULTS: Clinical data were obtained for 70 patients (mean age, 56.9 ± 9.4 years; 90.0% male) with a total number of 76 CTOs. At a median follow-up of 11.0 months (interquartile range, 7-18 months), both MACE and TLR rates were 4.3%. Two patients suffered from ischemia-driven TLR (1 patient at 6 months and 1 patient at 9 months after implantation). No death, MI, or stent thrombosis was observed during the follow-up period. CONCLUSION: Treatment of CTOs with BVS seems to be safe and effective, with a high technical success rate and acceptable MACE at short-term follow-up.

KW - bioresorbable vascular scaffold

KW - chronic total occlusion

KW - efficacy and safety

UR - http://www.scopus.com/inward/record.url?scp=84942899098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942899098&partnerID=8YFLogxK

M3 - Article

VL - 27

SP - 461

EP - 466

JO - Journal of Invasive Cardiology

JF - Journal of Invasive Cardiology

SN - 1042-3931

IS - 10

ER -